Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Ewing sarcoma
An EWSR1 fusion-driven sarcoma of children and young adults; relapsed disease has few options.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:13 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
92
Phase 1 to 3, interventional
For relapsed or refractory disease
48%
44 trial titles name relapsed, refractory or recurrent disease
Led by industry
18%
17 trials with a company as lead sponsor
3 of the 92 ewing sarcoma trials are Phase 3; 7 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of ewing sarcoma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 22 of 92 trials name no segment and are listed as Untagged.
Segment:All1L1L · Advanced or metastatic1L · Relapsed or refractoryAdvanced or metastaticEWSR1EWSR1 · 1L · Advanced or metastaticLocally advancedMaintenanceRelapsed or refractoryUntagged
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Cyclophosphamide H. Lee Moffitt Cancer Center and Research Institute | Advanced or metastatic | Small molecule | Ph3 | NCT07194044, NCT01946529, NCT01231906 |
| Etoposide H. Lee Moffitt Cancer Center and Research Institute | Advanced or metastatic | Other or not recognised | Ph3 | NCT07194044, NCT01946529, NCT01231906 |
| Ifosfamide H. Lee Moffitt Cancer Center and Research Institute | Advanced or metastatic | Small molecule | Ph3 | NCT07194044, NCT01946529, NCT01231906 |
| Cyclophosphamide National Cancer Institute (NCI) | 1L · Advanced or metastatic | Small molecule | Ph3 | NCT02306161 |
| Cyclophosphamide Children's Oncology Group | EWSR1 · 1L · Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT06820957 |
| Dexrazoxane Children's Oncology Group | Advanced or metastatic | Other or not recognised | Ph3 | NCT01231906 |
| Doxorubicin National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Doxorubicin Hydrochloride National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Doxorubicin Hydrochloride Children's Oncology Group | EWSR1 · 1L · Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT06820957 |
| Doxorubicin Hydrochloride Children's Oncology Group | Advanced or metastatic | Other or not recognised | Ph3 | NCT01231906 |
| Etoposide National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Etoposide Children's Oncology Group | EWSR1 · 1L · Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT06820957 |
| Etoposide Phosphate National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Ganitumab National Cancer Institute (NCI) | 1L · Advanced or metastatic | Antibody | Ph3 | NCT02306161 |
| Ifosfamide National Cancer Institute (NCI) | 1L · Advanced or metastatic | Small molecule | Ph3 | NCT02306161 |
| Ifosfamide Children's Oncology Group | EWSR1 · 1L · Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT06820957 |
| Irinotecan Hydrochloride Children's Oncology Group | EWSR1 · 1L · Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT06820957 |
| Regorafenib Children's Oncology Group | EWSR1 · 1L · Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT06820957 |
| Topotecan Hydrochloride Children's Oncology Group | Advanced or metastatic | Other or not recognised | Ph3 | NCT01231906 |
| Vincristine National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Vincristine Sulfate National Cancer Institute (NCI) | 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT02306161 |
| Vincristine Sulfate Children's Oncology Group | EWSR1 · 1L · Advanced or metastatic | Other or not recognised | Ph2/Ph3 | NCT06820957 |
| Vincristine Sulfate Children's Oncology Group | Advanced or metastatic | Other or not recognised | Ph3 | NCT01231906 |
| Temozolomide Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680, NCT06541262, NCT04337177, NCT04901702 +3 |
| Cyclophosphamide Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680, NCT01804634, NCT02574728, NCT07222735 |
| Fludarabine Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Relapsed or refractory | Other or not recognised | Ph2 | NCT01804634, NCT07222735, NCT01625351 |
| Irinotecan Eli Lilly and Company | Untagged | Other or not recognised | Ph2 | NCT05440786, NCT01858168, NCT04067115 |
| Irinotecan Pfizer | Relapsed or refractory | Other or not recognised | Ph2 | NCT03709680, NCT06541262, NCT04238819 |
| Palbociclib Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680, NCT03155620, NCT03526250 |
| Vincristine Milton S. Hershey Medical Center | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT06541262, NCT04890093, NCT06709495 |
| Cyclophosphamide Milton S. Hershey Medical Center | Untagged | Small molecule | Ph2 | NCT07321912, NCT04897321 |
| Doxorubicin H. Lee Moffitt Cancer Center and Research Institute | Advanced or metastatic | Other or not recognised | Ph2 | NCT07194044, NCT01946529 |
| Eflornithine Milton S. Hershey Medical Center | Untagged | Other or not recognised | Ph2 | NCT07321912, NCT06465199 |
| Ensartinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03213652, NCT03155620 |
| Erdafitinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03210714, NCT03155620 |
| Ivosidenib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT04195555 |
| Larotrectinib Sulfate National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213704 |
| Melphalan Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Relapsed or refractory | Other or not recognised | Ph2 | NCT01804634, NCT01625351 |
| Samotolisib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213678 |
| Selpercatinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT04320888, NCT03155620 |
| Sirolimus Emory University | Relapsed or refractory | Other or not recognised | Ph2 | NCT02574728, NCT01625351 |
| Tazemetostat National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213665 |
| Temozolomide Eli Lilly and Company | Untagged | Small molecule | Ph2 | NCT05440786, NCT01858168 |
| Temozolomide H. Lee Moffitt Cancer Center and Research Institute | Advanced or metastatic | Small molecule | Ph2 | NCT07194044, NCT01946529 |
| Tipifarnib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT04284774, NCT03155620 |
| Ulixertinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03698994, NCT03155620 |
| Vincristine H. Lee Moffitt Cancer Center and Research Institute | Advanced or metastatic | Other or not recognised | Ph2 | NCT07194044, NCT01946529 |
| Abemaciclib Eli Lilly and Company | Untagged | Small molecule | Ph2 | NCT05440786 |
| Abemaciclib Eli Lilly and Company | Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT04238819 |
| AMXT 1501 Dicaprate Milton S. Hershey Medical Center | Untagged | Other or not recognised | Ph1/Ph2 | NCT06465199 |
| Association of pembrolizumab + cabozantinib Institut Bergonié | Advanced or metastatic | Antibody | Ph2 | NCT05182164 |
| bevacizumab St. Jude Children's Research Hospital | Advanced or metastatic | Antibody | Ph2 | NCT01946529 |
| Cabozantinib National Cancer Institute (NCI) | 1L · Relapsed or refractory | Small molecule | Ph2 | NCT02867592 |
| Cabozantinib Nationwide Children's Hospital | Maintenance | Small molecule | Ph2 | NCT05135975 |
| Cabozantinib S-malate National Cancer Institute (NCI) | 1L · Relapsed or refractory | Small molecule | Ph2 | NCT02867592 |
| Cabozantinib S-malate National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT02243605 |
| CD146/HER2 CAR-T cells Essen Biotech | Advanced or metastatic | Cell therapy | Ph1/Ph2 | NCT07066982 |
| Celecoxib Emory University | Relapsed or refractory | Small molecule | Ph2 | NCT02574728 |
| Consolidation BuMel Institut Curie | 1L | Other or not recognised | Ph2 | NCT03011528 |
| Cyclophosphamide Memorial Sloan Kettering Cancer Center | 1L | Small molecule | Ph2 | NCT01864109 |
Showing the 60 most advanced of 182 programs.
Assets over time
92 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Cyclophosphamide | National Cancer Institute (NCI) | |
| Cabozantinib | Children's Hospital of Philadelphia | |
| Lurbinectedin | Jazz Pharmaceuticals | |
| Ensartinib | National Cancer Institute (NCI) | |
| Abemaciclib | Eli Lilly and Company | |
| Palbociclib | Pfizer | |
| Regorafenib | Institute of Mother and Child, Warsaw, Poland | |
| Eflornithine | Milton S. Hershey Medical Center | |
| Vincristine | H. Lee Moffitt Cancer Center and Research Institute | |
| LY2880070 | Memorial Sloan Kettering Cancer Center | |
| dasatinib | City of Hope Medical Center | |
| Multiple sarcoma-specific CAR-T cells and sarcoma vaccines | Shenzhen Geno-Immune Medical Institute | |
| Sarcoma-specific CAR-T cells | Shenzhen Geno-Immune Medical Institute | |
| Zilovertamab vedotin | Merck Sharp & Dohme LLC | |
| Tipifarnib | National Cancer Institute (NCI) | |
| Erdafitinib | National Cancer Institute (NCI) | |
| Zanzalintinib | Northwestern University | |
| Selpercatinib | National Cancer Institute (NCI) | |
| Naxitamab | Anna Raciborska | |
| Silmitasertib | Milton S. Hershey Medical Center | |
| Dinutuximab beta, Sirolimus and Irinotecan | University Hospital, Strasbourg, France | |
| GD2-CART01 | Bambino Gesù Hospital and Research Institute | |
| Entrectinib | Hoffmann-La Roche | |
| pH Low Insertion Peptide-exatecan Conjugate CBX-12 | Children's Oncology Group | |
| Ulixertinib | National Cancer Institute (NCI) | |
| Tegavivint | Children's Oncology Group | |
| LX-101 | M.D. Anderson Cancer Center | |
| Cabozantinib S-malate | National Cancer Institute (NCI) | |
| Ivosidenib | National Cancer Institute (NCI) | |
| Zoledronic acid | University of Florida |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT06820957 Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Single-country: United States (8 sites) Decision brief → | Ph2/Ph3 | Children's Oncology Group | terminated | 2025-02-11 | 2026-06-30 |
| NCT02306161 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma 3 countries, 95% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2014-12-03 | 2021-03-31 |
| NCT01231906 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma 6 countries, 88% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2010-11-01 | 2020-03-31 |
| BONE DINIRRA · NCT07853105 Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Single-country: France (12 sites) Decision brief → | Ph1/Ph2 | University Hospital, Strasbourg, France | not yet recruiting | 2026-10-01 | 2031-02 |
| NCT07830667 A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat No sites listed Decision brief → | Ph1/Ph2 | Children's Oncology Group | not yet recruiting | 2026-09-21 | 2033-06-30 |
| NCT07781891 RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | not yet recruiting | 2026-08-24 | 2031-06-30 |
| NCT07444918 Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors No sites listed Decision brief → | Ph2 | Tianjin Medical University Cancer Institute and Hospital | not yet recruiting | 2026-03-03 | 2027-12-01 |
| NCT07321912 Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Single-country: United States (3 sites) Decision brief → | Ph2 | Milton S. Hershey Medical Center | recruiting | 2026-01-07 | 2031-06-01 |
| NCT07092306 A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma No sites listed Decision brief → | Ph2 | Tang Xiaodong | not yet recruiting | 2025-07-29 | 2027-05-01 |
| BAH2573-103 · NCT07066982 Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Essen Biotech | recruiting | 2025-07-15 | 2027-12-10 |
| DFMO · NCT06892678 DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Montefiore Medical Center | recruiting | 2025-03-25 | 2030-04 |
| NCT06709495 Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | David S Shulman, MD | recruiting | 2024-11-29 | 2028-11-01 |
| NCT06625190 Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Florida | recruiting | 2024-10-03 | 2030-02 |
| NCT06571734 XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Single-country: United States (1 site) Decision brief → | Ph2 | Northwestern University | recruiting | 2024-08-26 | 2028-07-01 |
| NCT06541262 Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors 2 countries, 96% of sites in the US Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-08-07 | 2030-11-01 |
| NCT06465199 Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Single-country: United States (14 sites) Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-06-18 | 2033-05 |
| NCT06395103 Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) 23 countries, 24% of sites in the US Decision brief → | Ph1/Ph2 | Merck Sharp & Dohme LLC | recruiting | 2024-05-01 | 2029-03-31 |
| PerVision · NCT06094101 Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Single-country: Germany (4 sites) Decision brief → | Ph1/Ph2 | University Hospital Tuebingen | recruiting | 2023-10-23 | 2027-06 |
| NCT05968768 To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Single-country: Poland (2 sites) Decision brief → | Ph2 | Anna Raciborska | recruiting | 2023-08-01 | 2027-05-01 |
| LiFFT · NCT05918640 Lurbinectedin in FET-Fused Tumors Single-country: United States (6 sites) Decision brief → | Ph1/Ph2 | Children's Hospital of Philadelphia | recruiting | 2023-06-26 | 2028-07-30 |
| NCT05734066 Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma 2 countries, 94% of sites in the US Decision brief → | Ph1/Ph2 | Jazz Pharmaceuticals | recruiting | 2023-02-17 | 2028-01-28 |
| NCT05440786 CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma 7 countries, 17% of sites in the US Decision brief → | Ph2 | Eli Lilly and Company | active not recruiting | 2022-07-01 | 2025-01-15 |
| Regbone · NCT05395741 Regorafenib in Patients With Refractory Primary Bone Tumors Single-country: Poland (2 sites) Decision brief → | Ph1/Ph2 | Institute of Mother and Child, Warsaw, Poland | completed | 2022-05-27 | 2025-09-12 |
| NCT05275426 A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | completed | 2022-03-11 | 2025-08-11 |
| PEMBROCABOSARC · NCT05182164 Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Single-country: France (10 sites) Decision brief → | Ph2 | Institut Bergonié | recruiting | 2022-01-10 | 2026-12 |
| NCT05135975 A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2021-11-26 | 2026-07 |
| NCT05071209 Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors 2 countries, 97% of sites in the US Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | active not recruiting | 2021-10-08 | 2024-09-30 |
| NCT05046314 A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma Single-country: China (8 sites) Decision brief → | Ph2 | Shanghai Pharmaceuticals Holding Co., Ltd | completed | 2021-09-16 | 2025-02-05 |
| NCT04901702 Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma 2 countries, 70% of sites in the US Decision brief → | Ph1/Ph2 | St. Jude Children's Research Hospital | recruiting | 2021-05-25 | 2026-12-31 |
| NCT04890093 Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | suspended | 2021-05-18 | 2026-12-31 |
| NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Single-country: United States (21 sites) Decision brief → | Ph1/Ph2 | Children's Oncology Group | recruiting | 2021-04-20 | 2028-06-30 |
| NCT04433221 Combination Immunotherapy Targeting Sarcomas Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2020-06-16 | 2029-05-31 |
| NCT04320888 Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial 3 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-03-25 | 2024-09-30 |
| NCT04284774 Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial 2 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-02-26 | 2024-03-31 |
| NCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma 8 countries, 48% of sites in the US Decision brief → | Ph1/Ph2 | Eli Lilly and Company | completed | 2020-01-23 | 2024-03-15 |
| NCT04195555 Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) 3 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2019-12-12 | 2025-03-31 |
| U01CA236220 · NCT04067115 SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients Single-country: United States (6 sites) Decision brief → | Ph1/Ph2 | Sarcoma Alliance for Research through Collaboration | completed | 2019-08-26 | 2025-04-24 |
| NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors 13 countries, 67% of sites in the US Decision brief → | Ph2 | Pfizer | completed | 2018-10-17 | 2024-08-26 |
| NCT03698994 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2018-10-09 | 2022-03-31 |
| NCT03526250 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2018-05-16 | 2023-03-31 |
| NCT03449901 ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer Single-country: United States (4 sites) Decision brief → | Ph2 | Washington University School of Medicine | completed | 2018-02-28 | 2022-07-08 |
| NCT03373097 Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Single-country: Italy (1 site) Decision brief → | Ph1/Ph2 | Bambino Gesù Hospital and Research Institute | active not recruiting | 2017-12-14 | 2026-12 |
| NCT03356782 Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2017-11-29 | 2029-12-31 |
| NCT03213652 Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) 4 countries, 97% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2025-09-30 |
| NCT03213704 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2024-09-30 |
| NCT03213678 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2023-09-30 |
| NCT03213665 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2022-03-31 |
| NCT03210714 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-07 | 2023-09-30 |
| NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) 4 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-05-16 | 2025-03-31 |
| CombinaiR3 · NCT03011528 First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3) Single-country: France (17 sites) Decision brief → | Ph2 | Institut Curie | completed | 2017-01-05 | 2022-08 |
| NCT02945800 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Single-country: United States (14 sites) Decision brief → | Ph2 | H. Lee Moffitt Cancer Center and Research Institute | completed | 2016-10-26 | 2024-11-19 |
| NCT02867592 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Single-country: United States (142 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2016-08-16 | 2021-06-30 |
| STARTRK-NG · NCT02650401 Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options 9 countries, 58% of sites in the US Decision brief → | Ph1/Ph2 | Hoffmann-La Roche | active not recruiting | 2016-01-08 | 2027-06-30 |
| AflacST1502 · NCT02574728 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Emory University | active not recruiting | 2015-10-14 | 2026-06 |
| REGOBONE · NCT02389244 A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas Single-country: France (19 sites) Decision brief → | Ph2 | UNICANCER | completed | 2015-03-17 | 2024-10-25 |
| NCT02243605 Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma Single-country: France (11 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2014-09-18 | 2019-06-30 |
| NCT01946529 Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | completed | 2013-09-19 | 2015-08 |
| NCT01864109 Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2013-05-29 | 2027-05 |
| NCT01804634 Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Single-country: United States (3 sites) Decision brief → | Ph2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | recruiting | 2013-03-05 | 2027-01 |
| NCT00840047 Methionine PET/CT Studies In Patients With Cancer Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2009-02-10 | 2027-07-27 |
| NCT00788125 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | City of Hope Medical Center | terminated | 2008-11-10 | 2010-04-30 |
| NCT00186992 Radiation Therapy to Treat Musculoskeletal Tumors Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2005-09-16 | 2023-09-15 |
| GD2CART-BEV · NCT07897968 GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Single-country: Germany (1 site) Decision brief → | Ph1 | Universität Münster | not yet recruiting | 2026-10-27 | 2031-09-30 |
| NCT07695311 EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT Single-country: United States (1 site) Decision brief → | Ph1 | Rabi Hanna | not yet recruiting | 2026-07-10 | 2029-10 |
| NCT07297979 Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) 2 countries, 77% of sites in the US Decision brief → | Ph1 | Amgen | recruiting | 2025-12-22 | 2030-05-26 |
| NCT07222735 Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2025-10-30 | 2030-11-05 |
| NCT07197554 A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies Single-country: United States (6 sites) Decision brief → | Ph1 | SEED Therapeutics, Inc. | recruiting | 2025-09-29 | 2029-12-31 |
| METTSEO · NCT07194044 Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes Single-country: United States (21 sites) Decision brief → | Ph1 | H. Lee Moffitt Cancer Center and Research Institute | recruiting | 2025-09-26 | 2030-10 |
| SABRE · NCT07172958 Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Single-country: United States (2 sites) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2025-09-15 | 2041-12 |
| NCT06926283 A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors Single-country: China (4 sites) Decision brief → | Ph1 | Hangzhou DAC Biotechnology Co., Ltd. | recruiting | 2025-04-13 | 2030-04 |
| NCT06839703 International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma Single-country: Germany (5 sites) Decision brief → | Ph1 | Prof. Dr. Dr. Birgit Burkhardt | recruiting | 2025-02-21 | 2027-03-01 |
| NCT06566092 Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants Single-country: United States (5 sites) Decision brief → | Ph1 | Iovance Biotherapeutics, Inc. | terminated | 2024-08-22 | 2026-06-19 |
| NCT06156410 Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas Single-country: United States (4 sites) Decision brief → | Ph1 | Children's Hospital of Philadelphia | recruiting | 2023-12-05 | 2027-11 |
| NCT06008483 A Dose Finding Study to Treat Bone Tumor(s) Single-country: United States (4 sites) Decision brief → | Ph1 | QSAM Therapeutics, Inc. | terminated | 2023-08-23 | 2024-08-08 |
| REGO-INTER-EWI · NCT05830084 Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma 6 countries, 0% of sites in the US Decision brief → | Ph1 | Gustave Roussy, Cancer Campus, Grand Paris | active not recruiting | 2023-04-26 | 2027-04 |
| NCT05605522 A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours 2 countries, 88% of sites in the US Decision brief → | Ph1 | 3B Pharmaceuticals GmbH | terminated | 2022-11-04 | 2024-07-19 |
| NCT05210374 Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas Single-country: United States (1 site) Decision brief → | Ph1 | Case Comprehensive Cancer Center | recruiting | 2022-01-27 | 2026-09-01 |
| NCT04995003 HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2021-08-06 | 2028-06-30 |
| NCT04897321 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2021-05-21 | 2027-03-01 |
| NCT04483778 B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2020-07-23 | 2040-12 |
| NCT04337177 Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Single-country: United States (11 sites) Decision brief → | Ph1 | Valent Technologies, LLC | active not recruiting | 2020-04-07 | 2026-12 |
| NYMC195 · NCT04308330 Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Single-country: United States (1 site) Decision brief → | Ph1 | New York Medical College | recruiting | 2020-03-16 | 2026-12-31 |
| NCT04084067 Indocyanine Green (ICG) Guided Tumor Resection Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | completed | 2019-09-10 | 2026-07-28 |
| NCT03715933 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas 6 countries, 65% of sites in the US Decision brief → | Ph1 | Inhibrx Biosciences, Inc | recruiting | 2018-10-23 | 2028-12 |
| NCT03635632 C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Single-country: United States (2 sites) Decision brief → | Ph1 | Baylor College of Medicine | active not recruiting | 2018-08-17 | 2023-05-16 |
| NCT03618381 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2018-08-07 | 2040-06 |
| NCT03514407 A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma 4 countries, 45% of sites in the US Decision brief → | Ph1 | Incyte Corporation | terminated | 2018-05-02 | 2020-06-25 |
| CLOVER-2 · NCT03478462 Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas 3 countries, 75% of sites in the US Decision brief → | Ph1 | Cellectar Biosciences, Inc. | active not recruiting | 2018-03-27 | 2027-06-30 |
| NCT02508038 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | University of Wisconsin, Madison | recruiting | 2015-07-24 | 2026-12 |
| NCT02013336 Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors Single-country: United States (5 sites) Decision brief → | Ph1 | South Plains Oncology Consortium | recruiting | 2013-12-17 | 2026-12 |
| NCT01858168 Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma Single-country: United States (5 sites) Decision brief → | Ph1 | Massachusetts General Hospital | completed | 2013-05-21 | 2024-11-01 |
| NCT01625351 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | completed | 2012-06-21 | 2020-02-10 |